Breaking News
September 25, 2018 - New therapeutic vaccine helps immune cells fight HPV-related head and neck cancer
September 25, 2018 - Environmentally-induced gene activity influences IQ test performance
September 25, 2018 - Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI
September 25, 2018 - FDA Approves Copiktra (duvelisib) Capsules for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
September 25, 2018 - Medical device company settles US case over false claims
September 25, 2018 - Trying to get answers: One woman’s quest for a diagnosis
September 25, 2018 - Lung cancer patients treated with invasive surgery more likely to become chronic opioid users
September 25, 2018 - Oxford VR raises £3.2m to boost innovation in VR for mental health problems
September 25, 2018 - Gene therapy approach could help treat mitochondrial diseases
September 25, 2018 - Few Yogurt Products Qualify As Low-Sugar
September 25, 2018 - Eye disease can cause blindness, and it’s on the rise
September 25, 2018 - Pawnshop density linked to gun-related suicides, Stanford study finds
September 25, 2018 - Pioneering procedure for common prostate condition offered by The London Clinic
September 25, 2018 - Number of people with respiratory diseases likely to increase if UK air pollution remains unchecked
September 25, 2018 - FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial
September 25, 2018 - New program to reduce harmful stress effectively improves mood in cancer patients
September 24, 2018 - Florence’s Lingering Threat: Mold – Drugs.com MedNews
September 24, 2018 - For professional baseball players, faster hand-eye coordination linked to batting performance
September 24, 2018 - Bill for later school start times is defeated, but Stanford sleep specialist isn’t
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Successful recovery from addiction means more than achieving abstinence
September 24, 2018 - New nanoplatform technology may reverse drug-resistance in renal cell carcinoma
September 24, 2018 - October 1918 marks the centenary of Spanish Flu that claimed more lives than World War I
September 24, 2018 - LGBT community reports more number of poor mental health days than general population
September 24, 2018 - New research suggests power of zebrafish as tool for cancer drug discovery
September 24, 2018 - New study finds height as possible risk factor for developing varicose veins
September 24, 2018 - Researchers compare weight loss results of online and in-person diabetes prevention program
September 24, 2018 - New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment
September 24, 2018 - Drug combination offers more effective care for patients suffering miscarriage
September 24, 2018 - Tallness linked to varicose veins, Stanford study says
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Ecstasy drug makes octopuses more social
September 24, 2018 - Immediate compression therapy could cut risk of complications after deep-vein thrombosis
September 24, 2018 - Transcatheter mitral valve repair reduces mortality for patients with mitral regurgitation
September 24, 2018 - First intracranial aneurysm patients treated with BRAVO Flow Diverter after CE mark approval
September 24, 2018 - ‘Physicians of the mouth’? Dentists absorb the medical billing drill
September 24, 2018 - People more likely to believe those with confident tone of voice than with accent
September 24, 2018 - Harmony Biosciences Presents 5-Year Data On Pitolisant At International Narcolepsy Symposium
September 24, 2018 - Blood test may identify gestational diabetes risk in first trimester
September 24, 2018 - Height may be risk factor for varicose veins | News Center
September 24, 2018 - King’s commemorates opening of new NMR facility with one-day symposium
September 24, 2018 - Eisai receives approval for partial label change of DC Bead device for transcatheter arterial embolization
September 24, 2018 - Using multi-level approach to reduce underage drinking among youths on rural reservations
September 24, 2018 - High-resolution genomic map gives scientists unprecedented view of brain development
September 24, 2018 - Researchers find impact of neurobehavioral symptoms on employment in adults with TBI
September 24, 2018 - Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD
September 24, 2018 - First evaluation of benefits, harms of Alzheimer’s screening for family members of older adults
September 24, 2018 - Ancora Heart announces positive data of study evaluating AccuCinch Ventricular Repair System
September 24, 2018 - Children of mothers using cannabis may start using it at an earlier age, finds study
September 24, 2018 - Gilead Sciences plans to launch authorized generic versions of Epclusa and Harvoni in the US
September 24, 2018 - Most patients who underwent transcatheter valve replacement experience prosthesis-patient mismatch
September 24, 2018 - Lumos acquires license for LUM-201 drug that promotes secretion of growth hormone
September 24, 2018 - New study provides basis for Air Canada to change its facial hair policy for aircrew
September 24, 2018 - Infant walkers lead to thousands of emergency visits for babies
September 24, 2018 - Genes predicting person’s height may provide clues about causes of varicose veins
September 24, 2018 - EPA Plan Will Maintain Carbon Emissions From Power Plants
September 24, 2018 - Characterizing pig hippocampus could improve translational neuroscience
September 24, 2018 - Element3 Health reports social and mental engagement play key role in overall health
September 24, 2018 - Paralympic medalists support Fight for Sight’s unique virtual event
September 24, 2018 - ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma
September 24, 2018 - Public awareness of urological conditions found to be alarmingly low across Europe
September 24, 2018 - Fitter Folks Suffer Milder Strokes: Study
September 24, 2018 - Novel botulinum toxin compound relieves chronic pain
September 24, 2018 - CHMP recommends approval of Gilenya for treatment of multiple sclerosis in children, adolescents
September 24, 2018 - National Friendly’s private medical insurance is a hit with women living in the South East
September 24, 2018 - Academics receive prestigious awards for achievements in blood pressure research
September 24, 2018 - Obese pregnant women can restrict weight gain safely with proper nutrition guidance
September 24, 2018 - CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer
September 24, 2018 - China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma
September 24, 2018 - A new approach for finding Alzheimer’s treatments
September 24, 2018 - USC research uncovers previously unknown genetic risk factor for dementia
September 24, 2018 - Study examining mental health among students finds significant disparities in treatment across race
September 24, 2018 - Breakthrough discovery paves way for future test to identify drowsy drivers
September 24, 2018 - Transcatheter mitral-valve repair in patients with heart failure
September 24, 2018 - Study opens new avenues for treatment of Laing distal myopathy
September 24, 2018 - Stroke Facts | cdc.gov
September 24, 2018 - Sarcolipin tricks muscle cells into using more energy, burning fat
September 24, 2018 - Enrollment in opioid controlled substance agreement reduces primary care visits
September 24, 2018 - UTA researchers patent new smart seat cushion technology that helps prevent painful ulcers
September 24, 2018 - Second HPV-Related Primary Cancers Common in Survivors
RA Biomarker Panel IDs Patients at High Risk for Cardiovascular Events

RA Biomarker Panel IDs Patients at High Risk for Cardiovascular Events

image_pdfDownload PDFimage_print

Action Points

  • Higher rheumatoid arthritis (RA) disease activity, as measured by a multi-biomarker disease activity (MBDA) panel of biomarkers, was associated with higher rates of hospitalized infections, myocardial infarction (MI), and coronary heart disease (CHD) events.
  • The 100-point MBDA system, based on a set of 12 protein biomarkers, has been shown to correlate well with disease activity in several RA cohorts, and is commercially available from Crescendo Biosciences under the name Vectra DA.

Higher rheumatoid arthritis (RA) disease activity, as measured by a multi-biomarker disease activity (MBDA) panel, was associated with higher rates of hospitalized infections, myocardial infarction (MI), and coronary heart disease (CHD) events, analysis of Medicare data indicated.

Higher MBDA test scores were associated with increased serious infection events (HR 1.32 per 10-unit score increment, 95% CI 1.23-1.41), Jeffrey R. Curtis, MD, MPH, of the University of Alabama at Birmingham and colleagues reported.

Scores higher than 30 also were associated with increased MI (HR 1.52, 95% CI 0.92-2.49) and CHD rates (HR 1.54, 95% CI 1.01-2.34), compared with scores less than 30.

“In this large RA population predominantly consisting of older individuals, higher MBDA scores were associated with increased risk for hospitalized infection, MI and CHD events,” they wrote in Annals of the Rheumatic Diseases.

“A strong dose–response gradient existed between MBDA scores and hospitalized infections (pneumonia and sepsis). The patterns for MI and CHD events suggested more of a threshold effect, where those with the lowest level of disease activity and inflammation were at lowest risk, but gradations with higher levels of the biomarker were relatively absent,” they added.

The 100-point MBDA system is based on a set of 12 protein biomarkers, shown to correlate well with disease activity in several RA cohorts. It is commercially available from Crescendo Biosciences under the name Vectra DA. A score under 30 is considered low, 30–44 moderate, and over 44 high.

For this analysis, the researchers used national Medicare fee-for-service claims from 2010 to 2014, linking that information to patient-specific MBDA scores supplied by Crescendo.

To be included in the study, a patient needed to have at least one valid MBDA score linked to Medicare claims and at least 365 continuous days of Medicare with Part D coverage before the first valid MBDA test date.

The researchers excluded patients who had an International Classification of Diseases (ICD)-9 diagnosis code for ankylosing spondylitis, inflammatory bowel disease psoriasis, psoriatic arthritis, systemic lupus erythematosus, malignancy (except non-melanoma skin cancer), polymyalgia rheumatica, and giant cell arteritis in the 12-month baseline period. They also excluded patients who had initiated any non-tumor necrosis factor biologic or synthetic targeted disease-modifying anti-rheumatic drugs (DMARDs) in the 183 days before the index date.

Patients who had a prior MI, coronary artery bypass grafting, or percutaneous coronary intervention were not included in the MI and CHD outcome.

Because MBDA scores could be affected by an evolving outpatient infection or MI, the researchers also excluded patients from the MI and CHD analysis if they had heart attacks or coronary events in the 7 days following the MBDA test. Similarly, they excluded patients from the serious infection outcome if they had a serious infection in the 14 days after the test.

A total of 17,433 patients were eligible for the serious infection analysis and 16,796 patients for the MI and CHD outcome. Overall, the average age was 69 years; 79% were women, 81% were white, and 38% were disabled. These patients used methotrexate (54%), oral glucocorticoids (53%), non-biologic DMARDs (40%) and biologics (17%) to treat their RA.

Characteristics of patients in lower MBDA categories suggested they were younger (a 3-year difference), had a lower burden of comorbidities, and used less glucocorticoids and more biologics than patients with higher MBDA scores.

After multivariable adjustment, higher MBDA scores were associated with statistically significantly higher rates of serious infection events and higher MI and CHD rates.

Because C-reactive protein, one of the MBDA biomarkers, might influence outcomes, the researchers performed sensitivity analyses excluding it and found similar results: a 1.5-fold (CHD) and 1.7-fold (MI) elevated risk for patients in the higher disease activity category compared with the lowest.

“The current study is novel in that it leveraged a large administrative data source linked to a laboratory test provider database to address a question that neither data source by itself could address,” the authors wrote.

The results should be interpreted in light of the study design, they noted. It included predominantly older adults and findings might not apply to younger RA patients.

“However, given that the prevalence of infectious and CHD risk factors generally increases with age, we would speculate that the associations between RA disease activity and the outcomes that we studied might be even stronger in younger patients with RA,” they wrote.

This analysis was supported in part by Crescendo Bioscience, which is part of Myriad Genetics.

Curtis is a consultant for Myriad Genetics and has received research grants from them.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-04-01T00:00:00-0400

last updated

Tagged with:

About author

Related Articles